Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer By Ogkologos - June 11, 2025 489 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the OASIS-4 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR A cut above: Making drug discovery more efficient using CRISPR August 16, 2022 EMA Recommends Granting a Marketing Authorisation for the Medicinal Product Nyvepria October 2, 2020 Immunotherapy Drug Tebentafusp Improves Survival in Advanced Uveal Melanoma April 29, 2021 Implementation of Molecular Tumour Board Portal Developed Under the Umbrella of... May 25, 2022 Load more HOT NEWS Cancer Survivors Face High Rates of Housing Insecurity Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated... EMA Recommends Granting a Marketing Authorisation for Lazertinib FDA Approves Imetelstat for Low- To Intermediate-1 Risk Myelodysplastic Syndromes with...
